---
title: "Vertex Pharmaceuticals just made a $10 billion acquisition worth watching"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293142937.md"
description: "The biotech's diversification efforts continue."
datetime: "2026-07-20T01:05:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293142937.md)
  - [en](https://longbridge.com/en/news/293142937.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293142937.md)
generator: "portal-rs"
---

# Vertex Pharmaceuticals just made a $10 billion acquisition worth watching

The biotech's diversification efforts continue.

### Related Stocks

- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)

## Related News & Research

- [Vertex Pharma EVP Jasper van Grunsven files initial beneficial ownership statement](https://longbridge.com/en/news/298639785.md)
- [Vertex (VRTX) Stock Still Looks Like A Bargain On Its 181% Run](https://longbridge.com/en/news/298484320.md)
- [Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis](https://longbridge.com/en/news/298806080.md)
- [Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference](https://longbridge.com/en/news/298804783.md)
- [CRISPR Therapeutics (CRSP) Stock Looks Fully Priced Despite Stronger Pipeline Data](https://longbridge.com/en/news/298362756.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**